This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cronos Group (CRON) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Cronos Group (CRON) closed the most recent trading day at $13.66, moving +1.79% from the previous trading session.
Zacks Investment Ideas feature highlights: Tilray, Canopy and Cronos
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Tilray, Canopy and Cronos
Why Marijuana ETF is on a High in 2019
by Sweta Killa
After being beaten down in the final quarter of 2018, pot stocks staged a nice comeback this year on the renewed appeal for riskier assets.
Tilray's Tuesday Slide Due to IPO Lockup Expiration
by David Borun
Tilray's biggest shareholder resolves to stay long for the foreseeable future
Tilray Shares Rally as Investor Plans Not to Sell Shares
by Zacks Equity Research
Tilray (TLRY) gains after Privateer Holdings decides not to sell shares in the first half of 2019.
Can Altria's Expansion in RRPs & Cannabis Enable a Revival?
by Zacks Equity Research
Altria (MO) strives to expand in RRPs and Cannabis to stay afloat, amid receding cigarette sales.
Cronos Group (CRON) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cronos Group (CRON) closed at $12.36 in the latest trading session, marking a -0.32% move from the prior day.
The Top Cannabis Investing Storylines to Watch in 2019
by Ryan McQueeney
Ryan McQueeney chats with Zacks Stock Strategist Dave Borun about the top cannabis investing storylines to watch in 2019, including new legal issues, the most exciting areas for growth, and a new model portfolio that will feature some of the industry's top stocks.
Altria (MO) Confirms Deal With JUUL, Unveils Savings Plan
by Zacks Equity Research
Altria's (MO) deal with JUUL to boost strength in reduced risk products realm. Further, the company reiterates earnings view for 2018.
Cronos Group (CRON) Stock Moves -0.36%: What You Should Know
by Zacks Equity Research
Cronos Group (CRON) closed at $11.13 in the latest trading session, marking a -0.36% move from the prior day.
Altria Likely to Invest in Juul to Bolster E-Cigarettes Unit
by Zacks Equity Research
Altria (MO) is undertaking efforts to boost smokeless offerings. Per market reports, the company is considering an investment in Juul.
Can Altria (MO) Rebound From a Terrible 2018?
by Zacks Equity Research
Stringent FDA regulations have led to fading cigarette sales that are plaguing the performance of Altria. Nevertheless, growth in RRPs looks encouraging.
Cronos Group (CRON) Stock Moves -0.88%: What You Should Know
by Zacks Equity Research
Cronos Group (CRON) closed at $11.28 in the latest trading session, marking a -0.88% move from the prior day.
4 Reasons Why Pot Stocks & ETF Could Be on a High in 2019
by Sanghamitra Saha
These are the factors that could send marijuana stocks and ETF high in 2019.
3 Pot Stocks to Watch on Farm Bill & News from Trump, May, Retail Earnings
by Ryan McQueeney
Ryan McQueeney discusses President Trump's latest comments on the trade war and the impending vote of confidence facing U.K. Prime Minister Theresa May. He also recaps earnings results from the retail sector. Later, he highlights three cannabis stocks to watch as the farm bill passes.
Implied Volatility Surging for Cronos Group (CRON) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Cronos Group (CRON) stock based on the movements in the options market lately.
Canopy Growth (CGC) Gains on Hemp Legalization, Institutional Interest
by Ryan McQueeney
Shares of Canopy Growth (CGC) were up more than 6% in late afternoon trading Tuesday, as investors expressed optimism about the Senate's hemp legalization bill and management's comments about interest from institutional investors.
The Zacks Analyst Blog Highlights: Altria, Cronos, Constellation, Canopy Growth and ETFMG Alternative Harvest
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Altria, Cronos, Constellation, Canopy Growth and ETFMG Alternative Harvest
Cronos Group (CRON) Soars on C$2.4B Investment from Altria
by Zacks Equity Research
Cronos Group (CRON) receives a significant boost with C$2.4-billion equity investment from tobacco giant Altria Group.
Cronos-Altria Deal Boost Marijuana ETF: Will This Continue?
by Sweta Killa
Altria investment in Canadian cannabis producer Cronos sparked a rally in the broad cannabis sector and the its ETF. Will the trend continue?
Company News For Dec 10, 2018
by Zacks Equity Research
Companies In The News Are: BIG,ULTA,CRON,MO,LULU
Are There Any Dividend-Paying Cannabis Stocks?
by Ryan McQueeney
Cannabis stocks have been one of the investing world's top stories in 2018, but for many, these speculative plays are far too unpredictable. Are there any stable, dividend-paying marijuana stocks to buy right now?
Company News For Dec 5, 2018
by Zacks Equity Research
Companies In The News Are: DG,AZO,RH,CRON,MO
Why Tesla Is a Buy-Ranked Stock & the Latest Cannabis Industry Buzz
by Ryan McQueeney
Ryan McQueeney discusses President Trump's "Tariff Man" tweets and recaps the latest news from the cannabis industry. Later, he chats with Brian Bolan about Tesla (TSLA), a Zacks Rank #1 (Strong Buy) stock.
Why Cannabis Stocks CRON & APHA Are Moving in Opposite Directions
by Ryan McQueeney
Shares of Cronos Group (CRON) and Aphria (APHA) extended their recent moves in opposite directions on Tuesday morning, as investors continued to digest major headlines related to the popular cannabis companies.